Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Heemann, U.
Right arrow Articles by Wenzel, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heemann, U.
Right arrow Articles by Wenzel, R. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 556-559
© 2002 European Renal Association-European Dialysis and Transplant Association

Editorial Comment

CMV prophylaxis: what is valid in 2002?

Uwe Heemann and Rene R. Wenzel

Department of Nephrology, University Hospital, Essen, Germany

Introduction

Over the last decades, kidney transplantation has developed into a standard treatment for end-stage renal failure. This was made possible by a variety of medical achievements such as marked improvements in immunosuppressive regimens. Unfortunately, immunosuppressive drugs always bear the risk of infectious diseases.

One of the most frequent infectious agents in the wake of transplantation is cytomegalovirus (CMV). CMV belongs to the group of herpes viruses and about 80% of adults are carriers. Whether or not CMV disease develops after transplantation depends on a variety of factors, particularly whether or not the donor and/or recipient are carriers of the virus [1].

Pathophysiology

CMV disease occurs most frequently if CMV-positive organs are transplanted into a CMV negative recipient. If the recipient is already CMV positive at the time of transplantation and the donor is negative, the recipient may develop a relapse/re-infection or, due to strain variations, a new infection with . . . [Full Text of this Article]

Assays for detection

Drugs for treatment and prevention

Therapeutic options

Summary

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?